Weighted registration of 123I‐FP‐CIT SPECT images improves accuracy of binding potential estimates in pathologically low striatal uptake

To test whether the use of a striatum weighted image may improve registration accuracy and diagnostic outcome in patients with parkinsonian syndromes (PS), weighted images were generated by increasing signal intensity of striatal voxels and used as intermediate dataset for co‐registering the brain image onto template. Experimental validation was performed using an anthropomorphic striatal phantom. 123I‐FP‐CIT SPECT binding ratios were manually determined in 67 PS subjects and compared to those obtained using unsupervised standard (UWR) and weighted registered (WR) approach. Normalized cost function was used to evaluate the accuracy of phantom and subjects registered images to the template. Reproducibility between unsupervised and manual ratios was assessed by using intra‐class correlation coefficient (ICC) and Bland and Altman analysis. Correlation coefficient was used to assess the dependence of semi‐quantitative ratios on clinical findings. Weighted method improves accuracy of brain registration onto template as determined by cost function in phantom (0.86 ± 0.06 vs. 0.98 ± 0.02; Student's t‐test, P = 0.04) and in subject scans (0.69 ± 0.06 vs. 0.53 ± 0.06; Student's t‐test, P < 0.0001). Agreement between manual and unsupervised derived binding ratios as measured by ICC was significantly higher on WR as compared to UWR images (0.91 vs. 0.76). Motor UPDRS score was significantly correlated with manual and unsupervised derived binding potential. In phantom, as well as in subjects studies, correlations were more significant using the WR method (BPm: R2 = 0.36, P = 0.0001; BPwr: R2 = 0.368, P = 0.0001; BPuwr: R2 = 0.300, P = 0.0008). Weighted registration improves accuracy of binding potential estimates and may be a promising approach to enhance the diagnostic outcome of SPECT imaging, correlation with disease severity, and for monitoring disease progression in Parkinsonian syndromes. J. Cell. Physiol. 228: 2086–2094, 2013. © 2013 Wiley Periodicals, Inc.

[1]  M Laruelle,et al.  Methyl 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylate in vitro binding to dopamine and serotonin transporters under "physiological" conditions. , 1994, Journal of neurochemistry.

[2]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[3]  Jan Booij,et al.  The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism , 2001, European Journal of Nuclear Medicine.

[4]  M. Kaufman,et al.  Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's‐diseased striatum , 1991, Synapse.

[5]  J. Seibyl,et al.  [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression , 2001, Neurology.

[6]  Ingeborg Goethals,et al.  Analysis of clinical brain SPECT data based on anatomic standardization and reference to normal data: an ROC-based comparison of visual, semiquantitative, and voxel-based methods. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  K Van Laere,et al.  Automated stereotactic standardization of brain SPECT receptor data using single-photon transmission images. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  P J Slomka,et al.  Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  Rainer Linke,et al.  [123I]IPT binding to the presynaptic dopamine transporter: variation of intra- and interobserver data evaluation in parkinsonian patients and controls , 2000, European Journal of Nuclear Medicine.

[10]  P. Seeman,et al.  The Dopamine Transporter Is Absent in Parkinsonian Putamen and Reduced in the Caudate Nucleus , 1991, Journal of neurochemistry.

[11]  J. Ashburner,et al.  Nonlinear spatial normalization using basis functions , 1999, Human brain mapping.

[12]  J. Langston,et al.  The parkinson's complex: Parkinsonism is just the tip of the iceberg , 2006, Annals of neurology.

[13]  Willibald Gerschlager,et al.  Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study , 2002, Movement disorders : official journal of the Movement Disorder Society.

[14]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[15]  Perry E Radau,et al.  Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  Marc Laruelle,et al.  Methyl 3β‐(4‐[125I]Iodophenyl)Tropane‐2β‐Carboxylate In Vitro Binding to Dopamine and Serotonin Transporters Under “Physiological” Conditions , 1994 .

[17]  S J Kish,et al.  [11C]RTI‐32 PET studies of the dopamine transporter in early dopa‐naive Parkinson's disease , 1997, Neurology.

[18]  M. Brin,et al.  Consensus Statement of the Movement Disorder Society on Tremor , 2008, Movement disorders : official journal of the Movement Disorder Society.

[19]  Vesna Sossi,et al.  PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. , 2005, Brain : a journal of neurology.

[20]  Jan Booij,et al.  Iodine-123-N-ω-Fluoropropyl-2β-Carbomethoxy-3β-(4-Iodophenyl)Tropane SPECT in Healthy Controls and Early-Stage, Drug-Naive Parkinson's Disease , 1998 .

[21]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.

[22]  Manuel Desco,et al.  Influence of the normalization template on the outcome of statistical parametric mapping of PET scans , 2003, NeuroImage.

[23]  W. Poewe Clinical measures of progression in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[24]  Werner Poewe,et al.  Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice , 2003, Movement disorders : official journal of the Movement Disorder Society.

[25]  D J Wyper,et al.  Correlation of Parkinson's disease severity and duration with 123I‐FP‐CIT SPECT striatal uptake , 2000, Movement disorders : official journal of the Movement Disorder Society.

[26]  Colin Studholme,et al.  Comparison of Statistical Parametric Mapping and SPECT Difference Imaging in Patients with Temporal Lobe Epilepsy , 2002, Epilepsia.

[27]  L. Deecke,et al.  Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  D. Jennings,et al.  Optimized, Automated Striatal Uptake Analysis Applied to SPECT Brain Scans of Parkinson's Disease Patients , 2007, Journal of Nuclear Medicine.

[29]  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.

[30]  S. Fahn Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[31]  P B Hoffer,et al.  SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  Colin Studholme,et al.  Normalized entropy measure for multimodality image alignment , 1998, Medical Imaging.

[33]  Irène Buvat,et al.  Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  V. Poutanen,et al.  Accuracy of a registration procedure for brain SPET and MRI: phantom and simulation studies. , 1997, Nuclear medicine communications.

[35]  P B Hoffer,et al.  Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  R. Djaldetti,et al.  Residual striatal dopaminergic nerve terminals in very long‐standing Parkinson's disease: A single photon emission computed tomography imaging study , 2011, Movement disorders : official journal of the Movement Disorder Society.

[37]  N. Verhoeff,et al.  Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  E. Tolosa,et al.  Role of DAT‐SPECT in the diagnostic work up of Parkinsonism , 2007 .

[39]  C. Halldin,et al.  Molecular Imaging of the Dopamine Transporter , 2010, The Journal of Nuclear Medicine.

[40]  M Koole,et al.  MRI guided segmentation and quantification of SPECT images of the basal ganglia: a phantom study. , 2001, Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society.

[41]  O. Pogarell,et al.  Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years , 2001, Nuclear medicine communications.

[42]  G Bravo,et al.  Estimating the reliability of continuous measures with Cronbach's alpha or the intraclass correlation coefficient: toward the integration of two traditions. , 1991, Journal of clinical epidemiology.

[43]  Piero Calvini,et al.  The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[44]  J. Seibyl,et al.  Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[45]  Eileen O. Smith,et al.  Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.

[46]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[47]  J. Booij,et al.  [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease , 2001, Journal of Neural Transmission.

[48]  A Pupi,et al.  European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands. , 2002, European journal of nuclear medicine and molecular imaging.

[49]  P J Slomka,et al.  Evaluation of linear registration algorithms for brain SPECT and the errors due to hypoperfusion lesions. , 2001, Medical physics.

[50]  J. Seibyl,et al.  Do dopamine agonists or levodopa modify Parkinson's disease progression? , 2002, European journal of neurology.

[51]  Karl J. Friston,et al.  Voxel-Based Morphometry—The Methods , 2000, NeuroImage.

[52]  Jean-Luc Anton,et al.  Region of interest analysis using an SPM toolbox , 2010 .